2018
DOI: 10.1007/978-3-319-93473-0_4
|View full text |Cite
|
Sign up to set email alerts
|

Vulnerability to Nontuberculous Mycobacterial Lung Disease or Systemic Infection Due to Genetic/Heritable Disorders

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
5
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
3
1
1

Relationship

2
3

Authors

Journals

citations
Cited by 5 publications
(5 citation statements)
references
References 100 publications
0
5
0
Order By: Relevance
“…Isolated NTM lung disease may occur de novo in normal lungs but is more likely to develop in those with pre-existing bronchiectasis or COPD. The three most common genetic disorders associated with bronchiectasis are CF, AAT deficiency, and PCD (3,4). Other disorders known to be associated with bronchiectasis include Williams-Campbell syndrome (cartilage defect), Mounier-Kuhn syndrome (elastin defect resulting in marked airway dilatation), and Sjogren's syndrome (dry, inspissated mucus leading to bronchiectasis) as well as sequelae from suboptimally treated pyogenic bacterial pneumonia or tuberculosis.…”
Section: Discussionmentioning
confidence: 99%
“…Isolated NTM lung disease may occur de novo in normal lungs but is more likely to develop in those with pre-existing bronchiectasis or COPD. The three most common genetic disorders associated with bronchiectasis are CF, AAT deficiency, and PCD (3,4). Other disorders known to be associated with bronchiectasis include Williams-Campbell syndrome (cartilage defect), Mounier-Kuhn syndrome (elastin defect resulting in marked airway dilatation), and Sjogren's syndrome (dry, inspissated mucus leading to bronchiectasis) as well as sequelae from suboptimally treated pyogenic bacterial pneumonia or tuberculosis.…”
Section: Discussionmentioning
confidence: 99%
“…Typically, these two species are both reported as "MAC," but their environmental sources differ, and there is evidence indicating differential pathogenicity and clinical disease severity between the two species [6,7]. Since MAC is ubiquitous in the environment and exposure is likely unavoidable, it is apparent that some form of host susceptibility must also be present for MAC lung disease to occur [3,4,8]. In that context, pulmonary MAC disease occurs primarily in patients with structural lung disease, especially bronchiectasis and emphysema, without demonstrable systemic immune suppression [3,4,8].…”
Section: Introductionmentioning
confidence: 99%
“…Since MAC is ubiquitous in the environment and exposure is likely unavoidable, it is apparent that some form of host susceptibility must also be present for MAC lung disease to occur [3,4,8]. In that context, pulmonary MAC disease occurs primarily in patients with structural lung disease, especially bronchiectasis and emphysema, without demonstrable systemic immune suppression [3,4,8]. Pathophysiologic questions are further complicated because MAC lung disease can evolve in two forms, either fibro-cavitary disease similarly to pulmonary tuberculosis (TB), or as a more indolent infection associated radiographically with nodules and bronchiectasis (nodular/bronchiectatic disease) [3][4][5].…”
Section: Introductionmentioning
confidence: 99%
“…Typically, these two species are both reported as "MAC," but their environmental sources differ, and there is evidence indicating differential pathogenicity and clinical disease severity between the two species (6,7). Since MAC is ubiquitous in the environment and exposure is likely unavoidable, it is apparent that some form of host susceptibility must also be present for MAC lung disease to occur (3,4,8). In that context, pulmonary MAC disease occurs primarily in patients with structural lung disease, especially bronchiectasis and emphysema, without demonstrable systemic immune suppression (3,4,8).…”
Section: Introductionmentioning
confidence: 99%
“…Since MAC is ubiquitous in the environment and exposure is likely unavoidable, it is apparent that some form of host susceptibility must also be present for MAC lung disease to occur (3,4,8). In that context, pulmonary MAC disease occurs primarily in patients with structural lung disease, especially bronchiectasis and emphysema, without demonstrable systemic immune suppression (3,4,8).…”
Section: Introductionmentioning
confidence: 99%